November 12, 2019 Guselkumab Safe, Efficient in Biologic-Naïve Patients with Active Psoriatic Arthritis In patients with active psoriatic arthritis, who are biologic-naïve, guselkumab (Tremfya, Janssen) improved joint and skin symptoms, physical function, and quality of life, and resolved enthesitis and dactylitis, according to a study presented at annual meeting of the American College of Rheumatology in Atlanta on November 12. Read more   ADVERTISEMENT Calcium Pyrophosphate Deposition Disease Linked to Major CV Events, Death Patients with calcium pyrophosphate deposition (CPPD) disease may be at an increased risk of major adverse cardiovascular events along with a higher mortality rate compared to those without the disease, according to a study presented at annual meeting of the American College of Rheumatology in Atlanta on November 12. Read more   Active Conventional, Biological Therapy Show Similar RA Remission Rates A large proportion of patients with rheumatoid arthritis achieved remission with either active conventional therapy or with one of three different biologic therapies, certolizumab, abatacept and tocilizumab, after 24 weeks of treatment, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.   EU Consensus Statement on Combined Therapy with Methotrexate Methotrexate (MTX) should be continued in most patients with active rheumatoid arthritis (RA) when biologic or targeted synthetic therapy is initiated, EU researchers reported in a poster presentation on November 12 at the annual meeting of the American College of Rheumatology in Atlanta.